Cargando…
Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
Targeting immune checkpoint molecules has become a major new strategy in the treatment of several cancers. Indoleamine 2,3-dioxygenase (IDO)-inhibitors are a potential next-generation immunotherapy, currently investigated in multiple phase I-III trials. IDO is an intracellular immunosuppressive enzy...
Autores principales: | Meireson, Annabel, Chevolet, Inès, Hulstaert, Eva, Ferdinande, Liesbeth, Ost, Piet, Geboes, Karen, De Man, Marc, Van de Putte, Dirk, Verset, Laurine, Kruse, Vibeke, Demetter, Pieter, Brochez, Lieve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982767/ https://www.ncbi.nlm.nih.gov/pubmed/29861865 http://dx.doi.org/10.18632/oncotarget.25393 |
Ejemplares similares
-
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma
por: Brochez, Lieve, et al.
Publicado: (2018) -
Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy
por: Brochez, Lieve, et al.
Publicado: (2021) -
Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma
por: Meireson, Annabel, et al.
Publicado: (2021) -
Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer
por: Ferdinande, L, et al.
Publicado: (2012) -
A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
por: De Wolf, Katrien, et al.
Publicado: (2017)